

May 17-18, 2021 | Virtually in CST | pharmamanworld.com

# **AGENDA**

MAY 17, 2021

8:50 - 9:00 am

#### **Chair's Welcome Address**





Charles L. Cooney
Robert T. Haslam Professor of Chemical Engineering,
Emeritus, & Faculty Director, Emeritus Deshpande
Center for Technological Innovation
MIT

9:00 - 9:30 am

# A Look into the Future: How Pharmaceutical Manufacturing Is Transforming to Bring Hope to Patients

- Highlighting what should the industry do differently to achieve an ambitious future where all patients can receive lifesaving medicines safely, swiftly, reliably and affordably
- Exploring how and where products will be made, and how those products will be delivered by adopting system-driven planning and automation capabilities, leveraging the power of data and advanced analytics
- Describing a patient-centric pipeline the industry needs in order to deliver transformative therapies for all humanity
- A glimpse of how the world will evolve as molecular complexity increases in the future for small molecules, blurring the boundaries between small and large molecules





**Sanat Chattopadhyay** EVP & President, Merck Manufacturing Division **Merck** 

9:35 - 10:05 am

#### **Keynote: Delivering Excellence While Navigating Transition**

- Highlighting how operations and manufacturing can think differently to pivot for crises and global events
- Preparing for M&A opportunities and adapting for a changing business model
- Discussing the importance of equity, leadership and people as catalysts of culture and change within the industry as we work to serve patients better





**Azita Saleki-Gerhardt** EVP, Operations **Abbvie** 



**Massachusetts Institute of Technology** 



Charles L. Cooney
Robert T. Haslam
Professor of Chemical
Engineering, Emeritus, &
Faculty Director, Emeritus
Deshpande Center for
Technological Innovation
MIT

## **ROOM 2 CHAIR**





Joe Ferreira Life Science Executive Loftware





Ryan Hamilton Business Development Leader Körber Pharma Software

10:10 - 10:40 am

#### BREAKOUT ROOM 1 STRATEGIC MANUFACTURING

#### **Emerging Stronger Together – Toward a New Normal for a Post-COVID World**

- Reflecting on how the covid-crisis enabled changes and drove unprecedented achievements in our industry
- Highlighting the challenges we will face in the future, in a World more uncertain than ever
- Reflecting on how Trust and Collaboration at all levels will be essential to strive and to continue serving patients and Public Health worldwide





Franck Chassant
Head of Rare Disease, Oncology
and Immunology Cluster (RDOI)
Sanofi

10:10 - 10:40 am

## **Reducing Drug Shortages...and High Prices**

- How hospital systems and philanthropies came together to establish their own supply chain for essential quality generic medicines
- Living the mission to make quality generic medicines accessible and affordable to everyone
- Improving the resiliency of the supply of essential medicines used in hospitals, often for critical care, day-to-day and during a pandemic
- Ensuring a safe and stable supply of essential medicines for U.S. patients

ROOM 2
QUALITY




**Donna Gulbinski**Chief Quality
& Regulatory Affairs Officer **Civica Rx** 

10:10 - 10:40 am

#### **Rethinking our Supply Chain to be Patient-Centric**

- Challenges biotech companies are facing as patients expectations are increasing
- Ensuring the end-to-end supply chain can respond in the face of fierce competition for innovation
- Leveraging data and analytics to increase value and service to patients
- Keeping patients central as external factors accelerate need for resiliency

BREAKOUT ROOM 3 SUPPLY CHAIN





Kimberly Lounds Foster SVP Global Supply Chain Bristol-Myers Squibb 12:00 - 12:30 pm

WORKSHOP

# Leveraging Predictive and Behavioral Analytics to Ensure Supply Chain Health and Assess Compliance Risks – Case Study

- Deployed predictive and behavioral analytics to identify recently launched investigations that may create product availability issues
- Implemented an automated management alarm and escalation system, emails and text messages, to accelerate closure of those investigations
- Leveraged outcomes of reviews of quality system documents, e.g. batch records, CAPAs, Change Controls, etc. to assess multiple dimensions of compliance risk





Jaime Velez
Co-Founder and
Managing Director
OQSIE

12:00 - 12:30 pm

**WORKSHOP** 

#### Digital Transformation: Leverage Technology to Meet the New Quality Management Demands

- Overview digital transformation and industry 4.0
- The opportunity for change Intelligent and connected technologies such as cloud computing, artificial intelligence (AI) ,Internet of Things (IoT) and Augmented Reality
- What are the challenges faced by manufacturers in the changing healthcare environment to meet new quality management demands
- How intelligent and connected technology can help overcome challenges to meet quality demands
  - Utilizing advance technologies to identify quality issues in early manufacturing process to minimize risk
  - Eliminating communication barriers between the shop floor and quality teams by using digital platform
  - Paperless documentation and workflow Automated and digitally connected processes to align manufacturing process
  - Better tracking and visibility proactive decisions using real-time data and analytics
  - Minimizing human errors to manufacture safe products
  - Equipping manufacturers to stay ahead of the competition and bring high-quality, safe products faster to the market
  - Allows continuous improvement during the manufacturing process
  - Managing quality requirements and high demand during global crisis such as COVID-19 and how to be prepared in the future
- Practical experience sharing and lessons learned





**Steve McCarthy**VP, Digital Innovation **Sparta Systems** 

12:00 - 12:30 pm

#### Striving to Achieve the Goals of the Digital Plant

- Know the current, actual shop-floor schedule and status in real-time
- Optimize production
- Arm your operators with the tools to respond to process challenges
- Enable changeovers and new product introductions faster

WORKSHOP BREAKOUT ROOM 3





Michalle Adkins
Director, Life Sciences
Consulting
Emerson Automation Solutions

1:30 - 2:00 pm

# BREAKOUT ROOM 1

MANUFACTURING

# Science that Will Change the World: Lessons Learned from Bringing the First RNAi Therapeutics to Market

- What is RNA interference (RNAi)?
- A brief journey from Nobel Prize to ONPATTRO® (patisiran)
- Lessons from building commercial-scale manufacturing and supply chain operations
- What's next?





Al Boyle
Chief Technical Operations
and Quality Officer
Alnylam Pharmaceuticals

1:30 - 2:00 pm

#### **Lessons Learned From COVID-19 to Reduce Drug Shortages**

- Health Authorities and Industry have found new ways to work together to reduce and avoid drug shortages as a result of the pandemic
- How have Post Approval changes (PAC) evolved from taking years to work through Regulatory approvals to now a matter of weeks and days?
- What can we learn from this new collaboration? How can we make this regulatory agility permanent?
- Chief Quality Officers (CQOs) from the top 25 pharmaceutical companies have developed a solution to reduce drug shortages and enhance innovation and continual improvement for marketed drug products and vaccines in the "1VQ on PAC" Initiative
- The solution is patient centric and science and risk-based built on the principles of ICH Q9 guidance, Quality Risk Management, and the regulatory flexibility described in ICH Q10 guidance, Pharmaceutical Quality System





**Anders Vinther**Site Head & VP Global Quality **Intarcia Therapeutics** 

1:30 - 2:00 pm

## Future of Supply Chains: Enabling a Strategic and Competitive Advantage

- Understanding key forces/tends likely to disrupt the supply chain, implications and getting ahead of it.
- Identifying opportunities and areas to create a strategic/competitive advantage
- Digital, data and analytics as a key enabler in creating a strategic advantage
- Talent, culture, mindset needed to create and sustain a strategic and competitive advantage.

ROOM 3
SUPPLY CHAIN





Dennis Nsenkyire
VP, Strategy & Deployment
Janssen Supply Chain
Johnson & Johnson

2:05 - 2:35 pm

## WORKSHOP BREAKOUT ROOM 1

#### **How One Life Science Company Gained Control of 32 Million Labels**

- Learn how this Life Science company streamlined label changes and quickly reacted to customer and regulatory labeling demands
- Understand the benefits of maintaining one source of truth for all label data and how it can trigger labeling from business transactions to drive labeling dynamically
- How one Life Science company standardizes on a single labeling solution to gain control of labeling across their organization
- Discover how this company ensures labeling consistency across the supply chain by minimizing label templates and using advanced business logic from the company's sources of truth





Richard Burton Life Science Account Executive Loftware

2:05 - 2:35 pm

#### The Rapid Adoption of Intelligent Manufacturing & Pharma 4.0 During COVID

- Learn how Apprentice leverages Al, AR, intelligent technology and Pharma 4.0 to drive smart, data-driven manufacturing operations to increase an organization's speed to market
- Hear about common use cases and how some of the world's leading life science organizations applied this technology during COVID to steady supply chains, better manage operations and increase speed to market
- How to easily deploy intelligent manufacturing execution and collaboration platforms to scale faster, from COVID to cancer
- How to optimize productivity with global, remote collaboration systems that have changed the way manufacturing teams resolve issues and communicate across teams in or out of the lab and suite







Angelo Stracquatanio
CEO
Apprentice.io

2:05 - 2:35 pm

## **Digital Supply Chain Management – Data Visualization, Optimization & Prediction**

- Explore the importance of sponsor and supplier collaboration in fostering digital innovation
- Learn how to align customer services and digital experiences
- Unravel the benefits of real-time supply chain visibility from production to distribution
- Experience the power behind PCI's first-of-its-kind digital platform

WORKSHOP BREAKOUT ROOM 3



YOUR BRIDGE BETWEEN LIFE-CHANGING THERAPIES AND PATIENTS



Morgan Brandt Global Director of Digital Products PCI Pharma Services

**Networking Break** 

2:35 - 3:50 pm

#### **ROUNDTABLE DISCUSSION**

Building Resilient Supply Chains with Al and Machine Learning



**Bill Green**VP Technology and
Solution Delivery **Adexa Inc.** 

#### **ROUNDTABLE DISCUSSION**

Efficient Innovation – Application of Lean Concepts to Drive Innovation in Pharmaceutical Development and Manufacturing



**AMGEN** 

Thomas Seewoester VP External Supply Operations Amgen

#### ROUNDTABLE DISCUSSION

Best Practices in Risk Management for Combination Products





Jon Cammack Chief Quality and Compliance Officer Nevakar

#### **ROUNDTABLE DISCUSSION**

Start-Up or Big Pharma: Challenges in Development, Transfer and Commercial Manufacturing

– A CDMO Perspective



tesa 🖊

Timo Taghizadeh Head of Business Development & Marketing tesa Labtec GmbH

#### **ROUNDTABLE DISCUSSION**

Managing the CMO Network: Integrating New Technology with Legacy Systems





Jean Bender VP Pharmaceutical Sciences & Technology Visterra Inc.

3:55 - 4:25 pm

# **Developing Manufacturing Practices at A Rapid Pace for the Creation of Cell and Gene Therapies**

- Exploring recent and significant milestones in the cell and gene therapy space
- Reviewing developments at bluebird bio to advance therapies through to commercialization
- Examining the technical, clinical, and manufacturing challenges involved in live modality therapies
- Exploring evolving health authority expectations for cell and gene therapies
- Finding ways to reduce costs and improve patient access





**Derek Adams**Chief Technology and
Manufacturing Officer **bluebird bio** 

# Planning for Biomanufacturing of the Future: Setting the Course for Successful Industrialization of New Therapeutic Modalities

- How mRNA technology as well as cell and gene therapies promise to revolutionize medicine and may enable curative approaches for hard to treat diseases
- Why open innovation and external partnering in discovery and product innovation works for both innovators and mature biopharma companies
- What are the biggest challenge of bringing these therapies to patients globally stepping up the pace of adoption of new technologies, current industry limitations in CMC capabilities and capacity bottlenecks
- Delivering success in industrializing cell and gene therapies requires vision, leadership, diverse talent, the right organizational set-up and the right culture
- Case study: Discussing how Bayer is leveraging its core strengths in advanced manufacturing of difficult to make biologics in defining its technological approaches, including process integration, intensification, automation and digitalization which form the basis for creating our next generation cell and gene manufacturing platforms





Jens Vogel SVP & Global Head of Biotech Bayer AG

5:00 - 5:05 pm

#### **Chair's Closing Address**





Charles L. Cooney
Robert T. Haslam Professor of Chemical Engineering,
Emeritus, & Faculty Director, Emeritus Deshpande
Center for Technological Innovation
MIT

MAY 18, 2021

8:50 - 9:00 am

#### **Chair's Welcome Address**





Charles L. Cooney
Robert T. Haslam Professor of Chemical Engineering,
Emeritus, & Faculty Director, Emeritus Deshpande
Center for Technological Innovation
MIT

9:00 - 9:30 am

#### The Vertex Story: Serial Innovation in Manufacturing

- Sharing Vertex's track record for serial innovation in manufacturing to create transformative medicines for people with serious diseases and high unmet medical needs
- Highlighting Vertex's success with small molecule continuous manufacturing in Cystic Fibrosis
- Transforming manufacturing in cell and genetic therapies for Sickle Cell Disease, Beta Thalassemia, and Type 1 Diabetes





E. Morrey Atkinson
SVP and Head of Commercial
Manufacturing and Supply Chain
Vertex Pharmaceuticals

9:35 - 10:05 am

#### Leading Global Supplies in Times of High Biologic Demands Now and After the Pandemic Crisis

- Strong wave of innovation and new Biologic therapies resulting in high demands
- Building flexible global capacities at various scales and multiple global locations to ensure reliable supplies and serve patients' needs worldwide
- Business continuity planning, crisis management, pandemic preparedness & implementation of additional specific protection
- Close collaboration, intensive and solution-oriented exchange with customers and partners to ensure global patient supplies
- Managing diverse and complex challenges through digital transformation
- Critical success factor: Operational excellence, capacity & capabilities expansion and our peoples dedication





Uwe Buecheler Corporate SVP Biopharmaceuticals Boehringer Ingelheim



Massachusetts Institute of Technology



Charles L. Coonev Robert T. Haslam Professor of Chemical Engineering, Emeritus, & Faculty Director, Emeritus Deshpande Center for Technological Innovation

## **ROOM 2 CHAIR**





Joe Ferreira Life Science Executive Loftware





Ryan Hamilton Business Development Leader Körber Pharma Software

10:10 - 10:40 am

# MANUFACTURING

#### A Scalable Manufacturing Platform for Global mRNA Vaccine Production

- 86% of the global population has yet to be vaccinated against Covid-19. It is likely that we will need to provide annual boosters to the majority of the world's population for the foreseeable future
- GreenLight has developed a unique mRNA manufacturing platform with the scalability to produce billions of doses a year in a cost-competitive manner, enough to catchup on vaccinating the world, and provide annual boosters, through Integrated, proprietary manufacturing platform less dependent on key raw materials supply
- GreenLight is developing its own COVID-19 vaccine candidate, currently finishing pre-IND studies, which has shown strong preclinical performance and is expected to enter the clinic later this year or early in 2022
- Our vaccine development and manufacturing platform is rapidly adaptable to address new variants of concern





Andrey J. Zarur Founder & CEO GreenLight Biosciences, Inc. 10:10 - 10:40 am

#### Integration and Transformation

- Overview of Takeda
- Learnings from Integration of two large pharma companies
- Global Quality roadmap and transformation of Quality Management Systems
- Ways of working during COVID-19
- Quality Culture







Traci Seaman
VP, Head of Global Quality
Strategy & Business Operations
Takeda

10:10 - 10:40 am

#### Partnering with Contract Research and Manufacturing Organizations: Opportunities and Challenges

- Moving from pure "outsourcing" to "selective integration
- Designing and implementing effective partnerships between client companies and CMOs/CDMOs
- Discussing strategies for building and maintaining trust and confidence with external partners
- Assuring that outsourcing work does not impact quality and compliance
- Presentation of several case studies discussing innovative strategic partnerships

BREAKOUT ROOM 3 SUPPLY CHAIN





Stephen Scypinski VP Pharmaceutical Technology Daiichi Sankyo

10:40 - 11:55 am

**Networking Break** 

10:40 - 11:15 am

**Roundtable Discussions** 

#### **ROUNDTABLE DISCUSSION**

Avoiding Costly Shutdowns:
Hygienic Design with PVC Wall
Cladding and Adhesive-Free Flooring





## ROUNDTABLE DISCUSSION

The Challenge to "Actually" Deliver a Digital Strategy

ر<sup>ال</sup> Bristol Myers Squibb ٔ ا



Brendan Hughes SVP Global Manufacturing Operations Bristol-Myers Squibb

#### **ROUNDTABLE DISCUSSION**

Big Pharma Vs Start-Up: Challenges and Opportunities for CMC Development of Small Molecules and Biologics





Saul Fink VP Pharmaceutical Development Goldfinch Bio 12:00 - 12:30 pm

# WORKSHOP BREAKOUT

#### Autonomous Planning of Production at Allergan — A Case Study

See how:

- S&0E is used to improve S&0P
- Demand prioritization to improve customer satisfaction
- Planners moved from weekly planning to daily execution





John Hosford COO Adexa Inc.

12:00 - 12:30 pm

## WORKSHOP BREAKOUT ROOM 2

#### **Enabling One-Click Tech Transfers**

- Facilitate knowledge management & collaboration from development to manufacturing, across internal functions such as R&D, PD, CMC, MSAT, Regulatory, Quality, Manufacturing Automation & Engineering, and CDMOs
- Conduct 'facility-fit' scenarios for end-to-end processes in real-time during drug development
- Generate end-to-end tech transfer process documents with the click of a button





Suraj Pai CEO Fluxa Inc.

12:30 - 1:30 pm

**Lunch Break / Open Networking** 

1:30 - 2:00 pm

#### BREAKOUT ROOM 1 STRATEGIC MANUFACTURING

# Connecting Program Strategy with Operations Strategy: Creating Lifecycle Connections Between Development, Commercial, and Manufacturing & Supply

- Linking the manufacturing workforce and resources to the company leadership when planning for launch, expansion, plateau, technological shifts, and loss of exclusivity
- Going beyond near-term S&OP to guide manufacturing through lasting decisions
- How the right people, data, and long-range planning can lead to setting up right-sized manufacturing and supply chains





Michael Boyson VP, Head of Product Operations, Oncology & Small Molecule, Strategy and Business Excellence Takeda 1:30 - 2:00 pm

**BREAKOUT** 

**ROOM 2** 

**QUALITY** 

#### **Building Quality into Development**

- Establish key values and cultural philosophies as the foundation for building Quality into development
  - Proactively collaborate with other functional lines to establish respect and transparency
  - Make risk-based decisions rooted in scientific merit
  - Change the perception: Quality and innovation are NOT mutually exclusive
  - Put patients first through integrity, trust, and accountability
- Create roles and tools which help perpetuate those values and philosophies
  - Quality Product Lead role
  - Efficient team structures and clear expectations
  - Knowledge management tools
  - Change management structure





Shannon Holmes
Director, Product
Development Quality
Biogen

2:05 - 2:35 pm

# BREAKOUT ROOM 1

MANUFACTURING

Challenges and Advancements in Mircobiome Manufacturing: A Small Biotech's Perspective

- Overarching nuances to Microbiome Production
- Assessing CMO capabilities vs decision to build in house
- Exploring the considerations of Vedanta's choice to build internally
- Lessons learned through Vedanta's journey to commercialize microbiome therapeutics





Daniel Couto
Chief Operating Officer
Vedanta Biosciences

2:05 - 2:35 pm

## **Digitization for Pharmaceutical Manufacturing**

- Aligning tech and business strategy
- Opportunities and lessons learned from the front line

BREAKOUT ROOM 2 PHARMA 4.0





Michele D'Alessandro VP and CIO, Manufacturing IT Merck

#### Panel: The Past, Present and Future of the Global Pharmaceutical Industry

- How our "new normal" is affecting our critical materials procurement and how do we adapt for the future?
- Examining changes, risks, opportunities within changing supply chains and manufacturing networks
- What does short term post-COVID19 Pharma Industry look like?
- Outlining the struggles and opportunities in executing a Digital Strategy and Transformation
- How do novel modalities with existing challenges cope with these new global constraints?
- Seismic shifts and emerging fault lines create lasting affects, what are they and how do they shape our industry in the years to come?





Andrey J. Zarur Founder & CEO GreenLight Biosciences, Inc.

# RESILIENCE



Pat Yang Vice Chairman & Co-Founder National Resilience, Inc.





Pascal Bécotte
Global Executive Committee,
Global Sector Leader –
Functional Practices,
Country Manager – Canada
& Managing Director
Russell Reynolds Associates

3:25 - 3:35 pm

#### **Chair's Closing Address**





Charles L. Cooney
Robert T. Haslam Professor of Chemical Engineering,
Emeritus, & Faculty Director, Emeritus Deshpande
Center for Technological Innovation
MIT